Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Equity Average (2016 - 2026)

Ocular Therapeutix has reported Equity Average over the past 13 years, most recently at $617.9 million for Q1 2026.

  • For Q1 2026, Equity Average rose 112.62% year-over-year to $617.9 million; the TTM value through Mar 2026 reached $617.9 million, up 112.62%, while the annual FY2025 figure was $484.8 million, 138.55% up from the prior year.
  • Equity Average for Q1 2026 was $617.9 million at Ocular Therapeutix, up from $456.3 million in the prior quarter.
  • Over five years, Equity Average peaked at $617.9 million in Q1 2026 and troughed at $5.5 million in Q3 2023.
  • A 5-year average of $212.4 million and a median of $249.6 million in 2024 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: plummeted 91.21% in 2023 and later skyrocketed 6570.16% in 2024.
  • Year by year, Equity Average stood at $40.8 million in 2022, then rose by 21.29% to $49.5 million in 2023, then skyrocketed by 574.22% to $333.7 million in 2024, then skyrocketed by 36.74% to $456.3 million in 2025, then skyrocketed by 35.43% to $617.9 million in 2026.
  • Business Quant data shows Equity Average for OCUL at $617.9 million in Q1 2026, $456.3 million in Q4 2025, and $282.1 million in Q3 2025.